{
  "first_published_at": "2011-03-04", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON111502", 
  "title": "Modafinil (Provigil): information to support safer use; now restricted to narcolepsy", 
  "tags": "{\"parsed_therapeutic\": [\"neurology\"], \"Audience:\": [\"Primary care\", \"Secondary care\"], \"Therapeutic area:\": [\"Neurology\"]}", 
  "_document_number": 160, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/adverse_icon.png", 
  "therapeutic_area": [
    "neurology"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Modafinil (Provigil): information to support safer use; now restricted to narcolepsy</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: March 2011</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!---->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div id=\"dsuSynopsis\" class=\"yellow\">\r\n\t\t\t\t\t\t\t\t\t<div class=\"dsuArticlePadding\">\r\n\t\t\t\t\t\t\t\t\t<span id=\"dsuSynopsisTitle\"><b>Summary</b></span>\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<br>Following European-wide restriction of use of modafinil to the narcolepsy indication, further information is available to support safer use, including: cautions for use; criteria for stopping treatment; and monitoring requirements during treatment<br>\t\r\n\t\t\t\t\t\t\t\t\t</div>         \t\t\r\n\t\t\t\t\t\t\t\t\t<div id=\"dsuSynopsisCut\">\r\n\t\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>Modafinil (Provigil) is a wakefulness-promoting agent that acts on the CNS. It is indicated for the treatment of excessive sleepiness in adults with narcolepsy, with or without cataplexy. The recommended starting dose is 200 mg a day.</p><p>A recent European review of the benefits and risks of modafinil has recently been completed, and information about the restricted use of this drug as a result of this review was published in the <a href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON090901\">August 2010 issue of Drug Safety Update</a>.</p><p>Also as a result of the review, further information and advice is available to support safer use of modafinil.</p><div class=\"dull_highlight\">\r\n\t\t\t<p><strong>New information and advice for healthcare professionals:</strong></p>\r\n\t\t\t<p><strong>Product information advises against use in the following groups:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>Those with uncontrolled hypertension or cardiac arrhythmias</li>\r\n\t\t\t\t<li>Children up to 18 years old</li>\r\n\t\t\t\t<li>Women who are pregnant or breastfeeding</li>\r\n\t\t\t</ul>\r\n\t\t\t<p><strong>Treatment discontinuation:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>Modafinil should be discontinued and not restarted in cases of:<br>    o&nbsp;Serious skin or hypersensitivity reactions<br>    o&nbsp;Psychiatric disorders such as suicidal ideation</li>\r\n\t\t\t</ul>\r\n\t\t\t<p><strong>Monitoring during treatment:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>A baseline electrocardiogram should be done before treatment initiation. Patients with abnormal findings should be further evaluated by specialists before modafinil treatment can be initiated</li>\r\n\t\t\t\t<li>Cardiovascular function&mdash;especially blood pressure and heart rate&mdash;should be monitored regularly. Modafinil should be discontinued in patients who develop arrhythmia or moderate to severe hypertension, and should not be restarted until the condition has been adequately evaluated and treated</li>\r\n\t\t\t</ul>\r\n\t\t\t<p><strong>Cautions for use:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>Modafinil should be used with caution in patients with a history of:<br>    o&nbsp;Psychosis, depression, or mania<br>    o&nbsp;Abuse of alcohol, drugs, or illicit substances</li>\r\n\t\t\t\t<li>Such patients should be monitored closely and advised to report any suspected adverse behaviours or thoughts. Patients should be assessed immediately and treatment stopped if appropriate</li>\r\n\t\t\t</ul></div><h2>Advice on treatment cessation</h2><p>Modafinil is no longer indicated for shift-worker sleep disorder and obstructive sleep apnoea. Patients should be advised to contact their doctor if they are unsure as to whether they should discontinue modafinil treatment. Although there is no need to stop treatment immediately, patients who wish to stop can do so at any time.</p><h2>Reporting of suspected adverse reactions</h2><p>Suspected adverse reactions to modafinil should be reported promptly via the <a href=\"http://www.yellowcard.gov.uk/\" target=\"_blank\">Yellow Card Scheme</a>.</p><p><strong>Further information:</strong></p><p>Letter for <a href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON111461\">healthcare professionals sent January 2011</a>&nbsp;</p><p>BNF section 4.4 <a href=\"http://bnf.org/bnf/bnf/current/68990.htm\" target=\"_blank\">CNS stimulants and drugs used for attention deficit hyperactivity disorder</a><br></p><p>&nbsp;</p><p><em>Article citation: Drug Safety Update March 2011, vol 4 issue 8: A1.</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>Modafinil (Provigil) is a wakefulness-promoting agent that acts on the CNS. It is indicated for the treatment of excessive sleepiness in adults with narcolepsy, with or without cataplexy. The recommended starting dose is 200 mg a day.</p><p>A recent European review of the benefits and risks of modafinil has recently been completed, and information about the restricted use of this drug as a result of this review was published in the <a href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON090901\">August 2010 issue of Drug Safety Update</a>.</p><p>Also as a result of the review, further information and advice is available to support safer use of modafinil.</p><div class=\"dull_highlight\">\r\n\t\t\t<p><strong>New information and advice for healthcare professionals:</strong></p>\r\n\t\t\t<p><strong>Product information advises against use in the following groups:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>Those with uncontrolled hypertension or cardiac arrhythmias</li>\r\n\t\t\t\t<li>Children up to 18 years old</li>\r\n\t\t\t\t<li>Women who are pregnant or breastfeeding</li>\r\n\t\t\t</ul>\r\n\t\t\t<p><strong>Treatment discontinuation:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>Modafinil should be discontinued and not restarted in cases of:<br>    o&#160;Serious skin or hypersensitivity reactions<br>    o&#160;Psychiatric disorders such as suicidal ideation</li>\r\n\t\t\t</ul>\r\n\t\t\t<p><strong>Monitoring during treatment:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>A baseline electrocardiogram should be done before treatment initiation. Patients with abnormal findings should be further evaluated by specialists before modafinil treatment can be initiated</li>\r\n\t\t\t\t<li>Cardiovascular function&#8212;especially blood pressure and heart rate&#8212;should be monitored regularly. Modafinil should be discontinued in patients who develop arrhythmia or moderate to severe hypertension, and should not be restarted until the condition has been adequately evaluated and treated</li>\r\n\t\t\t</ul>\r\n\t\t\t<p><strong>Cautions for use:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>Modafinil should be used with caution in patients with a history of:<br>    o&#160;Psychosis, depression, or mania<br>    o&#160;Abuse of alcohol, drugs, or illicit substances</li>\r\n\t\t\t\t<li>Such patients should be monitored closely and advised to report any suspected adverse behaviours or thoughts. Patients should be assessed immediately and treatment stopped if appropriate</li>\r\n\t\t\t</ul></div><h2>Advice on treatment cessation</h2><p>Modafinil is no longer indicated for shift-worker sleep disorder and obstructive sleep apnoea. Patients should be advised to contact their doctor if they are unsure as to whether they should discontinue modafinil treatment. Although there is no need to stop treatment immediately, patients who wish to stop can do so at any time.</p><h2>Reporting of suspected adverse reactions</h2><p>Suspected adverse reactions to modafinil should be reported promptly via the <a href=\"http://www.yellowcard.gov.uk/\" target=\"_blank\">Yellow Card Scheme</a>.</p><p><strong>Further information:</strong></p><p>Letter for <a href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON111461\">healthcare professionals sent January 2011</a>&#160;</p><p>BNF section 4.4 <a href=\"http://bnf.org/bnf/bnf/current/68990.htm\" target=\"_blank\">CNS stimulants and drugs used for attention deficit hyperactivity disorder</a><br></p><p>&#160;</p><p><em>Article citation: Drug Safety Update March 2011, vol 4 issue 8: A1.</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2011-03-01", 
  "date_last_modified": "2011-03-03", 
  "_assets": [], 
  "_item_id": 160, 
  "summary": "Following European-wide restriction of use of modafinil to the narcolepsy indication, further information is available to support safer use, including: cautions for use; criteria for stopping treatment; and monitoring requirements during treatment", 
  "body": "Article date: March 2011\n\nModafinil (Provigil) is a wakefulness-promoting agent that acts on the CNS. It is indicated for the treatment of excessive sleepiness in adults with narcolepsy, with or without cataplexy. The recommended starting dose is 200 mg a day.\n\nA recent European review of the benefits and risks of modafinil has recently been completed, and information about the restricted use of this drug as a result of this review was published in the [August 2010 issue of Drug Safety Update](http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON090901).\n\nAlso as a result of the review, further information and advice is available to support safer use of modafinil.\n\nNew information and advice for healthcare professionals:\n\nProduct information advises against use in the following groups:  \n  \n  * Those with uncontrolled hypertension or cardiac arrhythmias  \n  * Children up to 18 years old  \n  * Women who are pregnant or breastfeeding  \n  \nTreatment discontinuation:  \n  \n  * Modafinil should be discontinued and not restarted in cases of:  \no Serious skin or hypersensitivity reactions  \no Psychiatric disorders such as suicidal ideation  \n  \nMonitoring during treatment:  \n  \n  * A baseline electrocardiogram should be done before treatment initiation. Patients with abnormal findings should be further evaluated by specialists before modafinil treatment can be initiated  \n  * Cardiovascular function—especially blood pressure and heart rate—should be monitored regularly. Modafinil should be discontinued in patients who develop arrhythmia or moderate to severe hypertension, and should not be restarted until the condition has been adequately evaluated and treated  \n  \nCautions for use:  \n  \n  * Modafinil should be used with caution in patients with a history of:  \no Psychosis, depression, or mania  \no Abuse of alcohol, drugs, or illicit substances  \n  * Such patients should be monitored closely and advised to report any suspected adverse behaviours or thoughts. Patients should be assessed immediately and treatment stopped if appropriate  \n  \n## Advice on treatment cessation\n\nModafinil is no longer indicated for shift-worker sleep disorder and obstructive sleep apnoea. Patients should be advised to contact their doctor if they are unsure as to whether they should discontinue modafinil treatment. Although there is no need to stop treatment immediately, patients who wish to stop can do so at any time.\n\n## Reporting of suspected adverse reactions\n\nSuspected adverse reactions to modafinil should be reported promptly via the [Yellow Card Scheme](http://www.yellowcard.gov.uk/).\n\nFurther information:\n\nLetter for [healthcare professionals sent January 2011](http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON111461) \n\nBNF section 4.4 [CNS stimulants and drugs used for attention deficit hyperactivity disorder](http://bnf.org/bnf/bnf/current/68990.htm)  \n\n\n \n\nArticle citation: Drug Safety Update March 2011, vol 4 issue 8: A1.\n"
}